Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab
Allergy · 2025-07 · 80 (7) · 1899-1911
DOI: 10.1111/all.16434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 18.12.2024. Verfasst von Nuria Contreras und 16 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada - Nemesio Díez (IMMA-ND), Universidad San Pa…. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Omalizumab, Anti-Asthmatic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ISCIII, FEDER "Investing in your future" for the thematic network and cooperative research centers ARADyAL, RICORS "Red de Enfermedades Inflamatorias (REI)".
Abstract (Originalsprache)
Rationale
Biologics are becoming increasingly important in the management of severe asthma. However, little is known about the systemic immunometabolic consequences of Th2 response blockage.
Objectives
To provide a better immunometabolic understanding of the effects of mepolizumab and omalizumab treatments by identifying potential biomarkers for monitoring.
Methods
In this exploratory longitudinal study severe asthmatic patients were followed for 18 months after initiating mepolizumab ( n = 36) or Omalizumab ( n = 20) treatment. Serum samples were collected before, 6, and 18 months after treatment. Targeted omic approaches were performed to analyze inflammatory metabolites ( n = 35) and proteins ( n = 45). Multiomic integration was performed individually for each treatment applying supervised analysis Data Integration Analysis for Biomarker discovery using Latent cOmponents (DIABLO) framework. Then, potential biomarkers were confirmed using multivariate ROC analyses and correlated with clinical variables along treatment. Measurements and Main Results Mepolizumab and omalizumab were both effective (improved clinical variables) and showed different and specific metabolic and protein profiles in severe asthmatic patients during treatment. Multiomic integration and multivariate ROC analyses identified specific biomarkers, such as arachidonic acid, palmitoleic acid, oleic acid, propionylcarnitine, bilirubin, CCL11, and TNFSF10, which can explain the differences observed with Mepolizumab treatment over 18 months and significantly correlate with clinical improvement. However, no significant biomolecules and no discriminative multivariate ROC curves were found for Omalizumab treatment.
Conclusions
Our results provide a comprehensive insight into the differential effects of mepolizumab and omalizumab on the immunometabolic kinetics of the inflammatory response in severe asthma. We identified a set of biomolecules with potential for monitoring mepolizumab treatment which could be useful for personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada - Nemesio Díez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
- Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.
- Servicio de Alergia, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
- Servicio de Alergia, Hospital Universitario de La Princesa, Instituto De Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain.
- Servicio de Neumología, Hospital Universitario de La Princesa, Instituto De Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain.
- Departamento de Matemáticas y Ciencia de Datos, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
ORCID-Profile: Nuria Contreras, Andrea Escolar-Peña, María I Delgado-Dolset, Paloma Fernández, David Obeso, Elena Izquierdo, Heleia González Cuervo, José Ángel Cumplido, Victoria Múgica, Carolina Cisneros, Santiago Angulo-Díaz-Parreño, Coral Barbas, Carlos Blanco, Teresa Carrillo, Domingo Barber, Alma Villaseñor, María M Escribese
Förderung
- ISCIII
- FEDER "Investing in your future" for the thematic network and cooperative research centers ARADyAL
- RICORS "Red de Enfermedades Inflamatorias (REI)"
- Fundación Mutua Madrileña
- San Pablo CEU University Foundation
- FPI-CEU predoctoral fellowship
- Instituto de Salud Carlos III
- Fundación Universitaria San Pablo CEU
Zitieren
APA
Contreras, N., Escolar-Peña, A., Delgado-Dolset, M. I., Fernández, P., Obeso, D., Izquierdo, E., Cuervo, H. G., Cumplido, J. Á., Múgica, V., Cisneros, C., Angulo-Díaz-Parreño, S., Barbas, C., Blanco, C., Carrillo, T., Barber, D., Villaseñor, A., & Escribese, M. M. (2025). Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab. Allergy, 80(7), 1899-1911. https://doi.org/10.1111/all.16434
Vancouver
Contreras N, Escolar-Peña A, Delgado-Dolset MI, Fernández P, Obeso D, Izquierdo E, et al. Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab. Allergy. 2025;80(7):1899-1911. doi:10.1111/all.16434
BibTeX
@article{Contreras2025,
author = {Contreras, Nuria and Escolar-Peña, Andrea and Delgado-Dolset, María I and Fernández, Paloma and Obeso, David and Izquierdo, Elena and Cuervo, Heleia González and Cumplido, José Ángel and Múgica, Victoria and Cisneros, Carolina and Angulo-Díaz-Parreño, Santiago and Barbas, Coral and Blanco, Carlos and Carrillo, Teresa and Barber, Domingo and Villaseñor, Alma and Escribese, María M},
title = {Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab},
journal = {Allergy},
year = {2025},
volume = {80},
number = {7},
pages = {1899--1911},
doi = {10.1111/all.16434}
}
EUVIMED